Synthesis of PLA-b-PEG Multiblock Copolymers for Stealth Drug Carrier Preparation.

Richard Quesnel and Patrice Hildgen*

Faculté de Pharmacie, Université de Montréal, C.P. 6128 Succursale Centre-ville, Montréal (Québec), Canada, H3C 3J7

* Author to whom correspondence should be addressed; e-mail: Patrice.hildgen@umontreal.ca.

Received: 17 May 2004 / Accepted: 2 July 2004 / Published: 31 January 2005

Abstract: An efficient method of preparing biodegradable and biocompatible multiblock copolymers from lactic acid and polyethylene glycol is proposed.

Keywords: Copolymers, multiblock, lactic acid, polyethylene glycol.

Introduction

Biodegradable polymers are studied in an increasing number of medical applications. They are used as drug carriers and controlled release systems [1-5]. Some authors are interested in the possibilities that a copolymer consisting of polylactic acid (PLA) and polyethylene glycol (PEG) can offer, but synthesis of PLA/PEG copolymers via trans-esterification with PLA [6, 7] or ring opening of (D,L)-lactide [8-12] can only produce di-block or tri-block copolymers. A multiblock copolymer composed of PLA and PEG is of considerable interest as a drug carrier, since the PLA segments could provide rigidity [13], while the PEG portions confer stealth behavior [14]. Stealth microparticles have the ability to evade the immune system. They can then circulate after injection for longer periods of time without any takeover from the immune system, thus increasing their effective lifespan. PEG can also offer a certain degree of hydrophilicity to the polymer that can be useful if we want to use it as a carrier for a hydrophilic drug.

We propose here an efficient synthesis method for a polyester-polyethylene multiblock copolymer where the polyester (A) blocks alternate with polyethylene oxide (B) blocks to form a repetitive sequence. Even though microspheres from triblock A-B-A copolymers can be made, we believe that in these microspheres, the A and B parts would discriminate from each other leaving the PEG (B) part mostly on the outside and the PLA (A) part on the inside. The use of a A-B-A-B-A copolymer would force the formation of small pockets of PEG within the microsphere thus facilitating the incorporation of
hydrophilic drugs. Since some of the PEG would be present at the surface, the copolymer would also keep its stealth behavior.

**Results and Discussion**

Table 1 shows the molecular weights of the triblock copolymers. Samples 1a to 1e were made using variety of PEG with different molecular weights at different percentages within the polymer, as described in the experimental section. Molecular weight for the triblock polymers was also deduced from the integration ratios of resonance from the tertiary proton of the PLA block at 5.2 ppm and the CH₂CH₂ of the PEG at 3.6 ppm. Since PEG bought commercially has a narrow mass distribution, the approximations from the integration ratios seem acceptable.

**Table 1:** Molecular weights of triblock copolymers

| Sample | \(\text{MW}_{\text{NMR}}\) (g/mol) | MN (g/mol) | MW (g/mol) | MW/MN | PEG % |
|--------|----------------------------------|-----------|------------|-------|-------|
| 1a     | 955.84                           | 926.29    | 1695.8     | 1.83  | 9.5   |
| 1b     | 1710.0                           | 900.84    | 1285.34    | 1.43  | 5.56  |
| 1c     | 2289.68                          | 2835.22   | 3595.42    | 1.27  | 9.12  |
| 1d     | 3769.6                          | 3863      | 4485       | 1.16  | 2.17  |
| 1e     | 15488                           | 13466     | 20623      | 1.53  | 0.51  |

Table 2 shows the molecular weights for the multiblock copolymers made from the previous triblock copolymers as described in the Experimental section. The increase in molecular weight shows that an average of 2 to 3 triblock copolymers were linked together to form multiblock copolymers.

**Table 2:** Molecular weights of multiblock copolymers

| Sample | MN (g/mol) | MW (g/mol) | MW/MN |
|--------|------------|------------|-------|
| 2a     | 1983.87    | 2670.60    | 1.35  |
| 2b     | 3646.71    | 8537.77    | 2.34  |
| 2c     | 6607.95    | 12040.6    | 1.82  |
| 3a     | 4246       | 5132       | 1.21  |
| 4a     | 18815      | 31309      | 1.66  |

For the triblock copolymers 1a-1e, typical spectra were obtained with peaks at 5.2 ppm corresponding to the tertiary PLA proton, at 3.6 ppm for the protons of the repeating units in PEG chain, at 4.3 ppm for the PEG connecting unit to the PLA block, and at 1.5 ppm for the pendant methyl group.
of the PLA chain. For the multiblocks 2a-2c, a peak around 2.7 ppm corresponding to the succinic acid residue is present. For the multiblock copolymer 3a, peaks corresponding to the protons in the adipic acid chain were detected at 3.0 and 2.3 ppm. As for copolymers 4a, only the peaks corresponding to the PEG chains were detected. Increase in PEG content in polymer 4a and the low molecular mass increase suggest that PEG was added to the end of the triblock copolymer giving an ending number of 3 PEG blocks and 2 PLA blocks.

Scheme 1

For each copolymer, 200 mg were dissolved in 3 mL of dichloromethane, and a thin film was cast on a glass slide. The films were dried under vacuum to remove any trace of solvent. Polylactic acid was used as a reference for the contact angle measurement. Contact angle measurements were made at 0 and 420 seconds. Table 3 shows that the copolymerization of PLA with PEG reduces the contact angle thus increasing the hydrophilicity of the copolymer compared to PLA alone.
Table 3: Contact angle for multiblock copolymers

| Polymer               | Contact angle (t = 0s) | Contact angle (t = 420s) |
|-----------------------|------------------------|--------------------------|
| PLA                   | 73.7                   | 49.3                     |
| Multiblock 2a (PEG 200) | 59.6                   | 38.6                     |
| Multiblock 2b (PEG 400) | 19.2                   | 2.0                      |
| Multiblock 2c (PEG 1450) | 17.6                   | 0.6                      |

This result has been corroborated by the measure of zeta potential of nanoparticles made of multiblock polymers. Pure PLA nanoparticles have a zeta potential about -40 mV. As expected, small amount of PEG in nanoparticles brings the zeta potential to a neutral value. So nanoparticles made from multiblock copolymers would retain their stealth behavior even if most of the PEG is embedded in the particles and only part of it shows at the surface of the particle.

Table 4: Zeta potential of nanoparticles made from PLA and multiblock copolymers

| NS composition (multiblock:PLA) | Size (nm) ± sd | ζ (mV) ± sd |
|---------------------------------|----------------|-------------|
| 40:60                           | 785.0 ± 169.8  | -1.68 ± 0.45|
| 50:50                           | 336.1 ± 92.5   | -1.28 ± 0.75|
| 60:40                           | 513.1 ± 107.9  | -0.64 ± 0.60|
| 70:30                           | 717.3 ± 141.4  | +0.64 ± 0.75|
| 80:20                           | 536.3 ± 42.4   | +0.94 ± 0.45|
| 90:10                           | 560.6 ± 72.5   | +1.10 ± 0.55|

Conclusions

Because of our concern to make polymers that have some potential as drug delivery systems, we discarded from the beginning the ones that didn’t show this potential. The polymers we searched for had to be solid at least at room temperature and preferably at body temperature. Consequently we didn’t follow-up on synthesis schemes that produced soft or liquid polymers. Copolymers that are shown here present the basic characteristics for the microencapsulation of a drug. They are solid enough to prepare microspheres and the presence of PEG ensures the stealth behavior. Others studies from Panoyan et al. already show in vitro and in vivo behavior for some of these polymers [15].

Experimental

General

Polyethylene glycol with molecular weight (g mol-1) of 200, 400 and 1500 were purchased from Aldrich Chemical Company, Inc. (Oakville, Ont., Canada) and were dried under vacuum in the presence of phosphorus pentoxide for 24 hours prior to use. (D,L)-lactide, tetraphenyltin, succinic acid and adipic
acid (Aldrich) received the same treatment. N,N-dimethylformamide was distilled over calcium hydride and kept on a 4Å molecular sieve prior to use. Thionyl chloride, 1-ethyl-3-[3-dimethylaminopropyl]-carbodiimide (EDC), 4-dimethylaminopyridine (4-DMAP), pyridine, methyl chloride, and chloroform were used as received from Aldrich Chemical Company. Molecular weights were measured by gel permeation chromatography using a Waters refractive index detector module. The number and weight average were determined by calibration obtained from polystyrene reference samples having narrow molecular weights distributions. The chemical composition of triblock (Scheme 1) and multiblock (Scheme 2) copolymers was characterized by $^1$H-NMR in CDCl$_3$ on a Bruker 400 MHz spectrometer. Contact angle measurement was made for samples 2a, 2b and 2c using a Tantec CAM-MICRO contact angle meter.

**Triblock PLA-PEG(200)-PLA (1a).** Triblock copolymers were synthesized by ring-opening polymerization of (D,L)-Lactide in the presence of PEG, as described by Cohn and Younes [13]. Briefly, PEG (molecular weight 200, 3.3 g, 16.5 mmol) was added to (D,L)-lactide (21.62 g, 150 mmol) in a round bottom single neck flask, to yield a PEG(200)/lactic acid ratio of 5%. Tetraphenyltin (0.1%) was used as a catalyst. The flask was purged with argon for 30 minutes and the reaction was carried at 180 °C for 6 hours under an argon inert atmosphere. The resulting polymer was precipitated in water from acetone, removing any unreacted PEG and (D,L)-lactide. The polymer was then dried under vacuum in the presence of phosphorus pentoxide. $^1$H-NMR $\delta = 5.0-5.3$ (m, 1H, CH), 4.2-4.4 (m, 2H, CH$_2$-OCO), 3.5-3.8 (m, 2H, CH$_2$), 1.3-1.8 (m, 3H, CH$_3$)

**Triblock PLA-PEG(400)-PLA (1b).** Compound 1b was synthesized as described for compound 1a using 16.5 mmol of PEG (molecular weight 400) and 150 mmol of (D,L)-lactide, to yield a PEG(400)/Lactic acid ratio of 5%. $^1$H-NMR $\delta = 5.1-5.3$ (m, 1H CH), 4.2-4.4 (m, 2H, CH$_2$-OCO), 3.6-3.8 (m, 2H, CH$_2$), 1.4-1.7 (m, 3H, CH$_3$)

**Triblock PLA-PEG(1500)-PLA (1c).** Compound 1c was synthesized as described for compound 1a using 16.5 mmol of PEG (molecular weight 1500) and 150 mmol of (D,L)-lactide, to yield a PEG(1500)/Lactic acid ratio of 5%. $^1$H-NMR $\delta = 5.0-5.3$ (m, 1H, CH), 4.2-4.4 (m, 2H, CH$_2$-OCO), 3.4-3.8 (m, 2H, CH$_2$), 1.3-1.7 (m, 3H, CH$_3$)

**Triblock PLA-PEG(400)-PLA (1d).** Compound 1d was synthesized as described for compound 1a using 8.3 mmol of PEG (molecular weight 400) and 158.3 mmol of (D,L)-lactide, to yield a PEG(400)/Lactic acid ratio of 2.5%. The amount of tetraphenyltin was reduced to 0.01%. $^1$H-NMR $\delta = 5.0-5.3$ (m, 1H, CH), 4.2-4.4 (m, 2H, CH$_2$-OCO), 3.6-3.8 (m, 2H, CH$_2$), 1.4-1.7 (m, 3H, CH$_3$); $^{13}$C-NMR $\delta = 16.5$ (CH$_3$), 69.0 (CH$_2$), 70.4 (CH), 169.2 (CO)

**Triblock PLA-PEG(1500)-PLA (1e).** Compound 1e was synthesized as described for compound 1a using 1.5 mmol of PEG (molecular weight 1500) and 150 mmol of (D,L)-lactide, to yield a PEG(1500)/Lactic acid ratio of 0.5%. The amount of tetraphenyltin was reduced to 0.01%. Synthesis time was reduced from 6 hours to 3 hours. $^1$H-NMR $\delta = 5.1-5.3$ (m, 1H, CH), 4.2-4.4 (m, 2H, CH$_2$-OCO), 3.6-3.8 (m, 2H, CH$_2$), 1.4-1.8 (m, 3H, CH$_3$); $^{13}$C-NMR $\delta = 16.5$ (CH$_3$), 69.7 (CH$_2$) 70.3(CH), 169.2 (CO)
Multiblock PLA-PEG(200)-PLA-co-succinic (2a). Compound 1a was dried under vacuum over phosphorus pentoxide for 24 h prior to the reaction. A solution of compound 1a (roughly 5 mmol), succinic acid (5 mmol) and EDC (12.5 mmol) in N,N-dimethylformamide (10 mL) was made. The solution was poured in a round bottom single neck flask and the flask was purged with argon for 30 minutes. The temperature was then brought down to 0 °C and stirred under magnetic agitation for 2 hours. A solution of 4-DMAP (1.5 mmol) dissolved in N,N-dimethylformamide (5 mL) was then added under an argon inert atmosphere. The reaction was let to stir for 12 hours while the temperature was gradually brought up to 25 °C. The resulting polymer was precipitated in a 0.1N HCl solution to remove any unreacted compound and then vacuum dried over phosphorus pentoxide. $^1$H-NMR $\delta = 5.1-5.3$ (m, 1H, CH), 4.2-4.5 (m, 2H, CH$_2$-OCO), 3.6-3.8 (m, 2H, CH$_2$), 2.6-3.0 (m, 2H, CH$_2$), 1.3-1.8 (m, 3H, CH$_3$)

Multiblock PLA-PEG(400)-PLA-co-succinic (2b). Compound 2b was synthesized as above, using 1b instead of 1a. $^1$H-NMR $\delta = 5.1-5.3$ (m, 1H, CH), 4.2-4.4 (m, 2H, CH$_2$-OCO), 3.6-3.8 (m, 2H, CH$_2$), 2.7-3.0 (m, 2H, CH$_2$), 1.4-1.7 (m, 3H, CH$_3$)

Multiblock PLA-PEG(1500)-PLA-co-succinic (2c). Compound 2c was synthesized as above, using 1c instead of 1a. $^1$H-NMR $\delta = 5.1-5.3$ (m, 1H, CH), 4.2-4.4 (m, 2H, CH$_2$-OCO), 3.6-3.8 (m, 2H, CH$_2$), 2.8-3.0 (m, 2H), 1.4-1.7 (m, 3H, CH$_3$)

Multiblock PLA-PEG(400)-PLA-co-adipic (3a). A solution of thionyl chloride (900mg) in pyridine (10 mL) was prepared at 0 °C by adding the pyridine dropwise to the thionyl chloride over a period of 30 minutes. A solution of adipic acid (3 mmol) and compound 1d (3 mmol) in N,N-dimethylformamide (30 mL) was prepared and kept at 0 °C. This solution was added to the thionyl chloride/pyridine dropwise over a period of 1 hour at 0 °C. The temperature was then gradually raised to 25°C over a period of 12 hours. The resulting polymer was then precipitated in water and centrifuged at 5000 rpm for 5 minutes. The process was repeated 2 times with fresh water. The polymer was then freeze dried. $^1$H-NMR $\delta = 5.1-5.3$(m, 1H, CH), 4.2-4.4 (m, 2H, CH$_2$-OCO), 3.6-3.8 (m , 2H, CH$_2$), 2.8-3.0 (m, 2H, CH$_2$), 1.4-1.7 (m, 3H, CH$_3$); $^{13}$C-NMR $\delta = 16.45$ (CH$_3$), 68.8 (CH$_2$) 69.0(CH), , 162.5 (CO adipic),169,2 (CO)

Multiblock PLA-PEG(1500)-PLA-co-PEG (4a). ClOCl-PEG(1500)-COCl was prepared from a solution of HOOC-PEG(1500)-COOH in thionyl chloride. Thionyl chloride was removed by vacuum, leaving ClOCl-PEG(1500)-COCl. A solution of modified PEG (0.52 mmol) was prepared with chloroform (20 mL) and added to a solution of compound 1e (0.52 mmol) in chloroform (40 mL). DMAP (100 mg) in pyridine (1 mL) was then added to the previous solution and agitated for 3 hours. The polymer was precipitated in 1N HCl and the chloroform was removed by evaporation. The last step was repeated 2 times and the polymer was then dried under vacuum over phosphorus pentoxide. $^1$H-NMR $\delta = 5.1-5.3$ (m, 1H, CH), 4.2-4.4 (m, 2H, CH$_2$-OCO), 3.6-3.8 (m , 2H), 2.8-3.0 (m, 2H, CH$_2$), 1.4-1.7 (m, 3H, CH$_3$); $^{13}$C-NMR $\delta = 16.45$ (CH$_3$), 68.8 (CH$_2$) 69.0(CH), , 162.5 (CO),169.2 (CO)
References

1. Rosen, H.B.; Chang, J.; Wnek, G.E.; Linhardt, R.J.; Langer, R. Bioerodible polyanhydrides for drug delivery. *Biomaterials* **1983**, *4*, 131-133.

2. Peppas, N.A.; Sahlin, J.J. Hydrogels as Mucoadhesive and Bioadhesive materials: a review. *Biomaterials* **1996**, *17*, 1553-1561.

3. Ogawa, Y. Injectable microcapsules prepared with biodegradable poly(alpha-hydroxy) acids for prolonged release of drugs. *J. Biomat. Sci. Polym. E* **1997**, *8*, 391-409.

4. Jain, R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. *Biomaterials* **2000**, *21*, 2475-90.

5. Fournier, E.; Passirani, C.; Montero-Menei, C.; N. Benoit, J. P. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. *Biomaterials* **2003**, *24*, 3311-3331.

6. Piskin, E.; Kaitian, X.; Denkbas, E.B.; Kucukyavuz, Z. Novel PDLLA/PEG copolymer micelles as drug carrier. *J. Biomat. Sci. Polym. Ed.* **1995**, *7*, 359-373.

7. Celikkaya, E.; Denkbas, E.B.; Piskin, E. Rifampicin Carrying Poly (D,L-Lactide)/Poly (Ethylene Glycol) Microspheres: Loading and Release. *Artif. Organs* **1996**, *20*, 743-751.

8. Ronneberger, B.; Kao, W. J.; Anderson, J. M.; Kissel, T. In vivo biocompatibility study of aba triblock copolymers consisting of poly(l-lactic-co-glycolic acid) a blocks attached to central poly(oxyethylene) b blocks. *J. Biomed. Mat. Res.* **1996**, *30*, 31-40.

9. Zhang, X.C.; Jackson, J. K.; Wong, W.; Min, W. X.; Cruz, T.; Hunter, W. L.; Burt, H. M. Development of biodegradable polymeric paste formulations for taxol - an in vitro and in vivo study. *Int. J. Pharm.* **1996**, *137*, 199-208.

10. Zhu, K.J.; Xiangzhou, L.; Shilin, Y. Preparation, Characterisation, and Properties of Polylactide (PLA)-Poly(ethylene Glycol) (PEG) Copolymers: A potential Drug Carrier. *J. Appl. Polym. Sci.* **1990**, *39*, 1-9.

11. Youxin, L.; Kissel, T. Synthesis and properties of biodegradable ABA triblock copolymers consisting of poly (L-lactic acid) or poly (L-lactic-co-glycolic acid) A blocks attached to central poly (oxyethylene) B-block. *J. Control. Rel.* **1993**, *27*, 247-257.

12. Ferruti, P.; Penco, M.; D'Addato, P.; Ranucci, E.; Deghenghi, R. Synthesis and properties of novel block copolymers containing poly(lactic-glycolic acid) and poly(ethylene glycol) segments. *Biomaterials* **1995**, *16*, 1423-1428.

13. Cohn, D.; Younes, H. Biodegradable PEO/PLA block copolymers. *J. Biomed. Mat. Res.* **1988**, *22*, 993-1009.

14. Muller, R.H. *Colloidal carriers for controlled drug delivery and targeting: modification, characterization, and in vivo distribution*; CRC Press Inc.: Boca Raton, Florida **1991**; pp. 45-46.

15. Panoyan, A.; Quesnel, R.; Hildgen, P. Injectable nanospheres from a novel multiblock copolymer: cytocompatibility, degradation and in vitro release studies. *J. Microencapsul.* **2003**, *20*, 745-58.

© 2005 by MDPI (http://www.mdpi.org). Reproduction is permitted for noncommercial purposes.